Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.
about
RNA-Binding Proteins: Splicing Factors and DiseaseStructure based approaches for targeting non-coding RNAs with small moleculesThe unstable repeats--three evolving faces of neurological diseaseOral administration of erythromycin decreases RNA toxicity in myotonic dystrophyCell membrane integrity in myotonic dystrophy type 1: implications for therapyStructure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity.Ametantrone-based compounds as potential regulators of Tau pre-mRNA alternative splicing.Methods to enable the design of bioactive small molecules targeting RNA.Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitorNew trends in aminoglycosides use.MBNL proteins and their target RNAs, interaction and splicing regulation.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Defining RNA motif-aminoglycoside interactions via two-dimensional combinatorial screening and structure-activity relationships through sequencing.Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.Features of modularly assembled compounds that impart bioactivity against an RNA target.A dynamic combinatorial approach for identifying side groups that stabilize DNA-templated supramolecular self-assemblies.RNA toxicity and missplicing in the common eye disease fuchs endothelial corneal dystrophy.A Chemical Inhibitor of the Skp2/p300 Interaction that Promotes p53-Mediated Apoptosis.RNA Structures as Mediators of Neurological Diseases and as Drug Targets.Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAsRational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts.An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TAR-Dependent Transcription.Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats.Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.Structures of RNA repeats associated with neurological diseases.New developments in RAN translation: insights from multiple diseases.HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of Replication-Competent and Multi-Drug-Resistant HIV in Human Cells.Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1.A Ligand That Targets CUG Trinucleotide Repeats.Cells of Matter-In Vitro Models for Myotonic Dystrophy.
P2860
Q26823957-0854BC62-8A2C-48AE-B070-5E2C2C9043CFQ26858823-3B481F29-19D6-4812-985B-CCD2FC8849EDQ27025923-84528030-FCA6-4C13-A606-EF9DE9E64F57Q28272224-2535A7CC-8ABD-440F-BBCB-BEE018750524Q28544911-2FF59EFD-3B2E-4119-9453-3AB433672951Q30573524-E67C9162-8EBE-40FC-8323-7A5A8427F77BQ30867681-7375FCB2-5252-4268-9414-EAEB5FF214F0Q33609375-88F5DCB0-18E6-47EA-9F1C-0B559064A2B4Q33692781-B2D19F67-B0C3-42AF-AA55-031D1259947AQ33951177-0FBB5F52-53EE-4131-8A13-33C9904CB2F6Q34248811-F2C760F5-4551-46DE-8974-776F6E1EDB7BQ34489424-9C9EB064-A961-44E7-8531-175BCCB735BBQ34747084-922AB155-14A6-435E-A42B-7E86EFDAF1BFQ34786164-82FF03E7-69BF-4A1A-91D7-BEE06FE60F37Q34986416-CCD6C0A1-39C2-45C8-B29E-8C976BD6DFC2Q35139112-CA207FAC-FBE0-4FE7-ACEE-2DF2A5EAFF00Q35172880-FE34C9DE-A862-4DFD-923A-BFF47235C09DQ35848294-1B726AA4-78F9-48DB-ABCE-51542852EFBEQ35868044-02CCEFAE-58B5-40F1-A1DD-D0DCF71E524EQ36186164-EB9BA4DC-4948-4552-A1E3-BBA86DB1C86FQ37017309-616214BE-B375-4ACC-9DCC-BE3CE7539C5EQ37360833-634A8CC4-D58D-4BB7-96CB-4D1014B34E98Q37544898-BCFEB6C8-7C7F-40A3-9B05-1A0FED75DB43Q37562085-6A21732F-FF56-43FF-AEDD-42CC456C1ADEQ38430517-F50F2FC2-E67C-4D25-A3BB-38157F810472Q38994216-CA169AF5-1BA4-45A4-B6D1-274C417313A4Q39213248-080FF46D-93E0-417C-8EA9-1C210D52E5F6Q40225647-2C6DB9F9-AF8C-4C39-A9EE-A5345F35F448Q41997886-C38CC9A9-A9C2-4D7D-AF07-A54CF4601DC3Q51832854-EB160ECC-C740-4B30-AF0D-CDE421DBA25EQ55100992-C97BDB3F-7070-4959-8B6B-3D123FD0380C
P2860
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@ast
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@en
type
label
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@ast
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@en
prefLabel
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@ast
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@en
P2093
P2860
P356
P1433
P1476
Rational design of bioactive, ...... ses myotonic dystrophy type 1.
@en
P2093
Charles A Thornton
Jessica L Childs-Disney
Masayuki Nakamori
Matthew D Disney
Raman Parkesh
P2860
P304
P356
10.1021/CB3001606
P577
2012-11-07T00:00:00Z